Nova Eye MedicalELXMF -0.03%55 Days Payable is 89.30 as of Dec. 2025, which is 62% below its 10-year median of 234.51. GuruFocus rates ELXMF with a GF Score™ of 55/100 and a GF Value™ of $0.02. The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 63.57% on this metric.
The historical rank and industry rank for Nova Eye Medical's Days Payable or its related term are showing as below:
ELXMF'
s Days Payable Range Over the Past 10 Years
Min: 35.76 Med: 234.51 Max: 479.86
Current: 96.48
During the past 13 years, Nova Eye Medical's highest Days Payable was 479.86. The lowest was 35.76. And the median was 234.51.
ELXMF's Days Payable is ranked better than 63.57% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs ELXMF: 96.48
Nova Eye Medical's Days Payable
declined
from Dec. 2024 (137.70) to Dec. 2025 (89.30).
It may suggest that Nova Eye Medicalaccelerated paying its suppliers.
Nova Eye Medical Days Payable Related Terms
Nova Eye Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nova Eye Medical's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ELXMF) has a Days Payable of 89.30 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nova Eye Medical and its competitors. This is 62% below median its historical median of 234.51. Over the past decade, Nova Eye Medical's Days Payable has ranged from 35.76 to 479.86. According to the industry distribution chart, Nova Eye Medical ranks #290 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 36.4%.
Is Nova Eye Medical's Days Payable too high?
Nova Eye Medical's current Days Payable of 89.30 is 62% below median its 10-year median of 234.51. Over the past 10 years, this metric has ranged from a low of 35.76 to a high of 479.86. The Medical Devices & Instruments industry median Days Payable is 68.14. Nova Eye Medical's value of 89.30 is 31.1% above this industry median. Based on the distribution chart, Nova Eye Medical ranks #290 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nova Eye Medical has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #290 out of 796 companies for Days Payable. This puts Nova Eye Medical in the upper half of its industry. The industry median Days Payable is 68.14. Nova Eye Medical's value of 89.30 is 31.1% above this benchmark. Historically, Nova Eye Medical's own Days Payable has ranged from 35.76 to 479.86 over the past decade. While the company's 10-year median is 234.51 vs. the industry median of 68.14, Nova Eye Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Eye Medical's current Days Payable of 89.30 is 31.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current Days Payable is 89.30, which is 62% below median its own 10-year median of 234.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current Days Payable of 89.30. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current Days Payable is 89.30, which is 62% below median its 10-year median of 234.51 and 31.1% above the Medical Devices & Instruments industry median of 68.14. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current Days Payable is 89.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
Days Payable: 89.30 (62% below median its 10-year median of 234.51)
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
Industry Position: 31.1% above the Medical Devices & Instruments median (#290 of 796)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score
Get the complete analysis for ELXMF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
